News Search Results
Jul 02, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jul 02, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Jul 02, 2025, 09:07 ET X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins' "Hopkins on the Hill" Event
X-Therma Inc., a pioneering biotechnology company revolutionizing organ preservation and regenerative medicine, proudly announces its participation in the prestigious Hopkins on the Hill
More news about: X-Therma Inc.
Jul 02, 2025, 09:00 ET mAbxience Announces European Commission Approval of Denosumab Biosimilars
agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance
More news about: mAbxience
Jul 02, 2025, 09:00 ET mAbxience Announces European Commission Approval of Denosumab Biosimilars
agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance
More news about: mAbxience
Jul 02, 2025, 08:32 ET Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered
More news about: Curis, Inc.
Jul 02, 2025, 08:00 ET [iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
https://www.prnewswire.com/news-releases/intron-files-us-patent-for-three-novel-endolysin-based-drug-candidates-targeting-gram-negative-bacteria-302496380.html SOURCE iNtRON Biotechnology, Inc.
More news about: iNtRON Biotechnology, Inc.
Jul 02, 2025, 04:19 ET Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
facilitated over $100 million in investment deals. About Arbele Arbele Limited is a clinical-stage biotechnology company developing potential first-in-class and best-in-class immunotherapies for digestive tract cancers. With strategic
More news about: Arbele
Jul 01, 2025, 13:55 ET ISS National Lab Partners with AIAA to Expand ASCEND with Low Earth Orbit-Focused Sessions in 2025 and 2026
25 years of continuous human presence on the ISS and the valuable research the space station has enabled, including advancements in biotechnology, fundamental science, and technology development. At ASCEND, research teams and programmatic leaders will discuss the critical impact of the
More news about: International Space Station National Lab
Jul 01, 2025, 11:52 ET Transformer Services Market Size to Surpass USD 8.23 billion by 2031, at a CAGR of 6.9%, Experiences Growth Due to Increasing Demand for Electricity Across | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 01, 2025, 11:23 ET Global Market for Media, Sera, and Reagents in Biotechnology to Reach $9.3 Billion by 2029
is driving advances in biotechnology, diagnostics, and targeted therapies. Technological advances: Rapid technological advances are transforming industries by enhancing efficiency, innovation, and automation. These breakthroughs drive progress in biotechnology, healthcare, and other sectors,
More news about: BCC Research LLC
Jul 01, 2025, 11:15 ET Smart Infrastructure Market Size Projected to Hit USD 2,745.9 Billion at an 18.3% CAGR by 2031
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 01, 2025, 11:12 ET RS and Belden vanquish industrial cabling challenges
flex, bending, torsion, and random motion flex. This range is widely deployed in the automotive, industrial, machine tool, marine, medical, biotechnology, military, mining, petrochemical, semiconductor, solar, and wind power industries and well-suited for use in delta robots in addition to all the
More news about: RS
Jul 01, 2025, 10:45 ET Set-Top Box Market Size Set to Surpass USD 31.08 Billion by 2031, with CAGR of 3.1%, Rising Demand for High-Definition (HD) and Ultra-High-Definition (UHD) Content Propels | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 01, 2025, 10:15 ET Biosimilars Market Size to Hit $76.2 Billion by 2030 - Driving Value-Based Care for Drugmakers, Regulators & Emerging Markets | The Research Insights
approximately 54.9%.Conclusion: The biosimilars market is undergoing a transformation driven by advancements in biotechnology, evolving regulatory landscapes, and expanding manufacturing capabilities. The increasing prevalence of chronic diseases and the rising economic
More news about: The Research Insights
Jul 01, 2025, 08:45 ET BioMarin Announces Completion of Acquisition of Inozyme
counsel to Inozyme since its founding, served as legal counsel. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Jul 01, 2025, 08:00 ET Apnimed to Participate in Upcoming July Investor Conferences
Evercore's Emerging Private Biotech ConferenceDate: July 13 - 15, 2025 Event: BTIG Virtual Biotechnology Conference 2025Date: July 29 - 30, 2025 Apnimed will be hosting 1x1 investor meetings around
More news about: Apnimed, Inc.
Jul 01, 2025, 08:00 ET Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
DIEGO, July 1, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Jul 01, 2025, 07:30 ET Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Jul 01, 2025, 07:17 ET Nektar Therapeutics Announces Pricing of $100 Million Public Offering
July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public
More news about: Nektar Therapeutics
Jul 01, 2025, 07:00 ET Frontage Announces Expansion of Business in Canada with New Leadership
provider of comprehensive, high-quality R&D services, supporting Canada's vision to become a dynamic hub for biotechnology and pharmaceutical innovation." About Frontage (
More news about: Frontage Laboratories, Inc.
Jul 01, 2025, 06:30 ET Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Jul 01, 2025, 01:40 ET HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement
More news about: HanchorBio Inc.
Jun 30, 2025, 17:31 ET GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion | DelveInsight
highly targeted therapies. Pharmaceutical companies are increasingly investing in GPCR-focused pipelines, often in collaboration with biotechnology firms and academic research institutions. Strategic partnerships, licensing deals, and acquisitions are common, aiming to access novel chemistries
More news about: DelveInsight Business Research, LLP
Jun 30, 2025, 16:38 ET Announcement of fully underwritten rights issue
www.bergenbio.com About Oncoinvent ASA Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS